Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 6/20 | 0.51 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.51 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.51 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.51 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.51 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.51 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.51 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.51 |
| ▸ | FLT1 | P17948 | 2/20 | 0.51 |
| ▸ | FLT4 | P35916 | 2/20 | 0.51 |
| ▸ | GSK3B | P49841 | 2/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.51 |
| ▸ | PLK4 | O00444 | 1/20 | 0.51 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.51 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.51 |
| ▸ | INSR | P06213 | 1/20 | 0.51 |
| ▸ | CDK1 | P06493 | 1/20 | 0.51 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17442210 | 0.85 | PRKAB2 (0.57) | KDRPRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL17448653 | 0.81 | KDR (0.43) | KDRFLT1FLT4MARK3MKNK2 | |
| SCHEMBL17448595 | 0.81 | PCSK9 (0.41) | GSK3BDYRK1ARETKITACACB | |
| SCHEMBL17448608 | 0.81 | PRKAB1 (0.53) | KDRPRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL17448596 | 0.81 | ACVR1 (0.71) | KDRPRKAB1ACVR1BMPR1ABMPR1B | |
| SCHEMBL17448594 | 0.79 | ACVR1 (0.47) | KDRGSK3BNTRK1FGFR1FLT3 | |
| SCHEMBL17448542 | 0.78 | PRKAB2 (0.49) | KDRPRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL17448555 | 0.77 | GSK3B (0.48) | KDRPRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL17448550 | 0.77 | GSK3B (0.47) | KDRPRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL19110525 | 0.76 | PRKAB1 (0.67) | KDRPRKAB2PRKAG1PRKAA2PRKAA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170197968-A1 | Compositions and Methods for Inhibiting BMP | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-07-13 | — | — | US | disclosed |
| WO-2016011019-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BMP | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2016-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197968-A1 | Compositions and Methods for Inhibiting BMP | BMP1, BMP2, BMPR2 | KDR 217/4885PRKAB2 1983/4885PRKAG1 2129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.